EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open access · CC BY-NC-ND 4.0

Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study

M Segerdahl iD, M Rother, M M Halldin, T Popescu, K Schaffler

European Journal of Pain · 2024

DOI: 10.1002/ejp.2299 ↗

At a glance

Randomisierte kontrollierte Studie in European Journal of Pain, 2024. Written by M Segerdahl and 4 co-authors. Institution: AlzeCure Pharma AB, Huddinge, Sweden. Major MEDLINE topics: TRPV Cation Channels, Cross-Over Studies, Healthy Volunteers, Pain. Cited 13 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: AlzeCure Pharma AB.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

The TRPV1 receptor is a key molecule in pain generation. Previous development of oral TRPV1‐antagonists was halted due to systemic heat insensitivity and body temperature alterations. The present Phase 1b study investigated the efficacy, safety and plasma exposure of a topically administered TRPV1‐antagonist (ACD440 Gel) in healthy subjects.

Methods

The study comprised two parts. In part 1, 24 healthy subjects were included in this randomized double‐blind, placebo‐controlled, crossover trial. ACD440 Gel or Placebo was applied once daily and wiped off after 1 h, for 5 consecutive days. Assessments were done in normal skin, skin optimized for penetration (by stripping and occlusive gel application) and UVB‐irradiated skin. Pain induced by thermo‐nociceptive CO 2 laser impulses generated laser‐evoked potentials (LEPs), with readouts of peak‐to‐peak (PtP) amplitude in vertex‐EEG and pain assessments by VAS (0–100). Endpoints include effects at 1 hour post‐dose, AUC(Days 1–5) and AUC (0–24, Day 4) . In UVB‐irradiated skin, also pain on pinprick and skin redness were assessed. Part 2 explored the plasma pharmacokinetics of ACD440.

Results

ACD440 Gel reduced LEP PtP amplitude and VAS pain, p < 0.001, in all skin conditions, versus placebo. In UVB‐irradiated skin, pinprick pain was also reduced, p = 0.047. Effects were significant after 1 h, maintaining for at least 9 h. There were no adverse events or drug‐induced erythema. Plasma exposures of ACD440 were too low to establish an elimination half‐life of ACD400.

Conclusions

Topical ACD440 Gel demonstrated a significant analgesic effect on LEP, VAS score and pinprick pain, with low systemic exposures, supporting further clinical development. Significance This study demonstrates that the topical administration of a TRPV1‐antagonist, ACD440 Gel, has potential as a new treatment for painful conditions affecting the skin, such as chronic peripheral neuropathic pain, without any local or systemic side effects.

Subjects

MeSH terms (MEDLINE)

TRPV Cation ChannelsCross-Over StudiesHealthy VolunteersPainGelsHumansDouble-Blind MethodMaleAdultFemaleYoung AdultPain MeasurementMiddle AgedAdministration, TopicalSkinAnalgesicsLaser-Evoked PotentialsAdministration, Cutaneous

Substances

TRPV Cation ChannelsGelsTRPV1 receptorTRPV1 protein, humanAnalgesics

Authors and institutions

  • AlzeCure Pharma AB, Huddinge, Sweden.
  • Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden.
  • HPR Dr. Schaffler GmbH, Human Pharmacodynamic Research, Munich, Germany.

ORCID profiles: M Segerdahl

Funding

  • AlzeCure Pharma AB

Cite

APA

Segerdahl, M., Rother, M., Halldin, M. M., Popescu, T., & Schaffler, K. (2024). Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study. European Journal of Pain. https://doi.org/10.1002/ejp.2299

Vancouver

Segerdahl M, Rother M, Halldin MM, Popescu T, Schaffler K. Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study. European Journal of Pain. 2024. doi:10.1002/ejp.2299

BibTeX
@article{Segerdahl2024,
  author = {Segerdahl, M and Rother, M and Halldin, M M and Popescu, T and Schaffler, K},
  title = {Topically applied novel TRPV1 receptor antagonist, ACD440 Gel, reduces evoked pain in healthy volunteers, a randomized, double‐blind, placebo‐controlled, crossover study},
  journal = {European Journal of Pain},
  year = {2024},
  doi = {10.1002/ejp.2299}
}
Start for free →